The purpose of the present study was to evaluate whether a combination of Cisplatin or 5-FU with small molecule inhibitors (SMIs) of the PI3K/AKT pathway, BKM120 and MK2206, would re-sensitize lung cancer cells to chemotherapy and improve its efficacy. Here, AKT1 is linked to lung cancer.